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Abstract 
Background: Some studies have shown that switching patients from one tumor necrosis factor (TNF)-alfa 
inhibitor to another may be beneficial when they have an inadequate response or an adverse event.  
 
Objective: We sought to assess the variables predicting the efficacy of the second TNF-alfa inhibitor in 
patients discontinuing the first TNF-alfa inhibitor.  
 
Methods: Data from all 5423 consecutive patients starting TNF-alfa inhibitor therapy for psoriasis between 
September 2005 and September 2010 who were included in the Italian Psocare registry were analyzed.  
 
Results: In 105 patients who switched to a second TNF-alfa inhibitor who had complete follow-up data, 75% 
improvement in the Psoriasis Area Severity Index score (PASI 75) was reached by 29% after 16 weeks and 
by 45.6% after 24 weeks. Patients who switched because of secondary loss of efficacy (loss of initial PASI 
75 response) or adverse events/intolerance were more likely to reach PASI 75 than those who switched as a 
result of primary inefficacy (PASI 75 never achieved) (hazard ratio 2.7, 95% confidence interval 1.3-5.5 vs 
hazard ratio 2.0, 95% confidence interval 1.0-3.9 and 1, respectively).  
 
Limitations: There was a small number of patients with complete follow-up data.  
 
Conclusion: PASI 75 response in patients who switched from one antie-TNF-alfa agent to another was 
significantly reduced in patients who showed primary inefficacy of the first antie-TNF-alfa. 
 
